Yuan Dong, Xu Wenbo, Raza Faisal, Zafar Hajra, Guan Shuangxian, Wang Zhen, Ullah Kamran Hidayat, Shi Hongchao
Department of Emergency, JinTan Hospital Affiliated to JiangSu University, 500 Jintan Dadao, Jintan, Changzhou 213200, Jiangsu, China.
School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
Adv Pharmacol Pharm Sci. 2024 Nov 22;2024:2869332. doi: 10.1155/adpp/2869332. eCollection 2024.
High mortality and disability have been principally linked with traumatic brain injury (TBI) with this condition being a principal issue in public health. Currently, there is no reliable pharmaceutical agent to salvage the damage caused by TBI. Baicalein (BCL), a traditional Chinese medicine active ingredient, has preliminarily shown repair activity on brain injury. However, BCL has poor water solubility and bioavailability, which culminates in rapid elimination in vivo. Herein, we sought to solve the above-mentioned challenges that are associated with the application of this flavonoid by preparing BCL-loaded long-circulating liposomes (BLC-Lips) via thin-film hydration method. Subsequently, BLC-Lips were applied to TBI model mice to evaluate their effect on brain injury repair. The results showed that the prepared BLC-Lips exhibited smaller sized nanoparticles, excellent polydispersed index (PDI), and zeta ()-potential with stable property. After loading of BCL into the liposomes, we estimated the physicochemical properties of BLC-Lips to be roughly 87.98% (encapsulation efficiency [EE]) and 7.56% (loading capacity of the drug). Administration of BLC-Lips through oral route increased aqueous solubility, bioavailability, and time for in vivo circulation of BCL. Moreover, the BLC-Lips could improve outcomes of histological and neurological motor function and reduce inflammatory cytokines and neurotoxicity after TBI. Taken together, the long-circulating liposomes may serve as a new approach to potentially prolong drug circulation in vivo and increased bioavailability of BCL for TBI treatment.
高死亡率和残疾主要与创伤性脑损伤(TBI)相关,这种情况是公共卫生领域的一个主要问题。目前,尚无可靠的药物制剂来挽救TBI造成的损害。黄芩素(BCL)是一种中药活性成分,已初步显示出对脑损伤的修复活性。然而,BCL的水溶性和生物利用度较差,导致其在体内迅速消除。在此,我们试图通过薄膜水化法制备负载BCL的长循环脂质体(BLC-Lips)来解决与这种黄酮类化合物应用相关的上述挑战。随后,将BLC-Lips应用于TBI模型小鼠,以评估其对脑损伤修复的影响。结果表明,制备的BLC-Lips呈现出较小尺寸的纳米颗粒、优异的多分散指数(PDI)和ζ电位,性质稳定。将BCL负载到脂质体中后,我们估计BLC-Lips的物理化学性质为包封率(EE)约87.98%和药物负载量7.56%。通过口服途径给药BLC-Lips可提高BCL的水溶性、生物利用度和体内循环时间。此外,BLC-Lips可改善组织学和神经运动功能结果,并降低TBI后的炎性细胞因子和神经毒性。综上所述,长循环脂质体可能是一种潜在的延长药物在体内循环并提高BCL用于TBI治疗的生物利用度的新方法。